Chronic Myeloid Leukemia Archives - Page 4 of 46

Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.

A New Trend in Drug Development: Leveraging Data from Expanded Access

By

March 2, 2020

Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.

Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.

General Oncology

The Questionable Practice That Permeates Oncology Clinical Trials

By

Christina Bennett, MS

February 19, 2020

Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.

Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.

General Oncology

Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life

By

Helene Engler, PhD

February 13, 2020

Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.

Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.

Chronic Myeloid Leukemia

Oral Oncology Parity Laws Don’t Make Medications More Affordable

By

Jessica Wapner

February 7, 2020

Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.

The cancer field is not immune to the challenges of out-of-network and surprise billing.

General Oncology

The Unexpected Costs of Cancer Treatment: Out-of-Network Billing

By

Amber Dance, PhD

February 4, 2020

The cancer field is not immune to the challenges of out-of-network and surprise billing.

Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.

General Oncology

The FDA Approval Process Needs Refinement, Not a Total Overhaul

By

Randi Hernandez

January 14, 2020

Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.

This study led to the first clinical trial in humans to test trabectedin for CLL.

Chronic Myeloid Leukemia

Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial

By

Christina Bennett, MS

January 13, 2020

Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.